We then tested the tumor cell responses to a wide range of drugs that have been used for treatment of osteosarcoma, and found that RPN2 silencing increased the sensitivity to doxorubicin, methotrexate, and docetaxel (Figure 2f and Supplementary Figure S2). This evidence concerns the gene RPN2 and osteosarcoma.